MR1 and cancer: The fact that MR1*04 has a ligand binding site difference that precludes presentation of MAIT cell ligands might mean that this variant binds to cancer ligands better than other MR1 variants or that these ligands are more likely to be presented in the absence of competition from standard self and bacterial ligands that are unable to bind to MR1*04.